scholarly article | Q13442814 |
P2093 | author name string | Raghav Govindarajan | |
Nakul Katyal | |||
P2860 | cites work | Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) | Q24201081 |
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study | Q24600803 | ||
Electrical impedance myography as a biomarker to assess ALS progression | Q24615680 | ||
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial | Q24651555 | ||
From animal models to human disease: a genetic approach for personalized medicine in ALS | Q26741250 | ||
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? | Q26823418 | ||
Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases | Q28139487 | ||
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
Phase II/III randomized trial of TCH346 in patients with ALS | Q28241484 | ||
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis | Q28486263 | ||
Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury | Q28511628 | ||
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis | Q28728672 | ||
Electrodiagnosis in Persons With Amyotrophic Lateral Sclerosis | Q29013127 | ||
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation | Q29547561 | ||
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis | Q29619074 | ||
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial | Q30432762 | ||
Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. | Q30440341 | ||
Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis | Q30485762 | ||
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. | Q30494108 | ||
A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity | Q30626279 | ||
Empirical evidence of design-related bias in studies of diagnostic tests | Q30776370 | ||
Biomarkers in amyotrophic lateral sclerosis | Q33392844 | ||
Electrical impedance myography: Background, current state, and future directions | Q33666081 | ||
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). | Q33909851 | ||
Motor unit number estimation in human neurological diseases and animal models | Q34263978 | ||
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials | Q34327603 | ||
Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research | Q34401653 | ||
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study | Q34552316 | ||
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. | Q34584573 | ||
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial | Q34648924 | ||
A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis | Q35015986 | ||
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design | Q35210258 | ||
Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials | Q36148492 | ||
Diagnostic investigation and multidisciplinary management in motor neuron disease | Q36346085 | ||
ALS biomarkers for therapy development: State of the field and future directions | Q36479616 | ||
Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study | Q80140620 | ||
Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice | Q80786193 | ||
Test-retest reproducibility of 50 kHz linear-electrical impedance myography | Q83213101 | ||
[Analysis of reasons for the late diagnosis of amyotrophic lateral sclerosis] | Q83367680 | ||
Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial | Q83978302 | ||
Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis | Q84990896 | ||
Reproducibility of MUNIX in patients with amyotrophic lateral sclerosis | Q85001543 | ||
Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis | Q94947175 | ||
Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group | Q36892306 | ||
Protein biomarkers for amyotrophic lateral sclerosis | Q37157841 | ||
Motor unit number estimation in neuromuscular disease. | Q37198723 | ||
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights | Q37206683 | ||
Guidelines for preclinical animal research in ALS/MND: A consensus meeting | Q37698628 | ||
Effects of gender in amyotrophic lateral sclerosis | Q37825010 | ||
Emerging drugs for amyotrophic lateral sclerosis | Q37909351 | ||
CSF markers in amyotrophic lateral sclerosis | Q38007362 | ||
Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? | Q38260277 | ||
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial | Q39344567 | ||
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013. | Q39525418 | ||
Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage | Q40351989 | ||
A clinical trial of creatine in ALS. | Q40469445 | ||
Histological Bulbar Manifestations in the ALS Rat. | Q41137506 | ||
'Excitability changes of muscular responses to magnetic brain stimulation in patients with central motor disorders | Q41927184 | ||
Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial | Q42940220 | ||
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial | Q43239620 | ||
Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G(93A-Low) mice | Q43261428 | ||
Brain and plasma riluzole pharmacokinetics: effect of minocycline combination | Q43280641 | ||
Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial | Q44368657 | ||
The use of statistical MUNE in a multicenter clinical trial | Q45022449 | ||
Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis | Q45075692 | ||
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. | Q46281670 | ||
Modelling the effects of penetrance and family size on rates of sporadic and familial disease | Q47360537 | ||
The cortical silent period and amyotrophic lateral sclerosis | Q48183634 | ||
Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis | Q48355423 | ||
Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. | Q48874060 | ||
C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. | Q48923374 | ||
Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mut | Q49157605 | ||
Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. | Q50592658 | ||
Bayesian statistical MUNE method. | Q51915464 | ||
Degenerative Myelopathy in a Bernese Mountain Dog with a Novel SOD1 Missense Mutation | Q56627315 | ||
We have a problem: why have ALS trials been negative? | Q56929747 | ||
Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy | Q57129367 | ||
A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis | Q57666978 | ||
Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients | Q58125524 | ||
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS | Q58271878 | ||
Shortening the time to the diagnosis of amyotrophic lateral sclerosis: role of the neurologist | Q58281701 | ||
Preclinical research: Make mouse studies work | Q59058234 | ||
Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study | Q71654443 | ||
Transcranial magnetic stimulation as a diagnostic and prognostic test in amyotrophic lateral sclerosis | Q71832728 | ||
A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis | Q73089745 | ||
Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials | Q73194258 | ||
Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration | Q73348009 | ||
Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1 | Q79405492 | ||
Trial of celecoxib in amyotrophic lateral sclerosis | Q79794799 | ||
P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
P304 | page(s) | 521 | |
P577 | publication date | 2017-09-29 | |
P1433 | published in | Frontiers in Neurology | Q15817039 |
P1476 | title | Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement | |
P478 | volume | 8 |